The HPV Cellular Transactivator Brn-3a Can Be Used to Predict Cervical Adenocarcinoma and Squamous Carcinoma Precancer Lesions in the Developed and Developing Worlds

Table 1

Patients in Recife-Brazil and London-UK with rare and common forms of cervical precancer lesions plus a cervicitis control group showing the mean mRNA levels of Brn-3a and HPV E6 in cervical scrapes.

Women from Brazil
Pathology	Case patients.	Age	Brn-3a mRNA	HPV E6 mRNA
	No. (%)	Mean	Mean	Mean
Cervicitis	32 (38.5)	39.4	0.2^a∗	0.17^⋀b
SCC precancer	32 (38.5)	50.7	0.58*	0.55^⋀
			^∗𝑃=.000001	𝑃=.000002
AC precancer	17 (20.5)	44	0.47^a	0.4^b
			^a𝑃=.00033	^b𝑃=.001
SSCC	2 (2.5)	35	<0.1^†	<0.1^†
			^†0< negligible < 0.1	^†0< negligible < 0.1
Women From England
Pathology	Case patients.	Age	Brn-3a mRNA	HPV E6 mRNA
	No (%)	Mean	Mean	Mean
Cervicitis	32 (60.4)	37.2	0.21*	0.17^⋀
SCC precancer	17 (32.1)	28.8	0.46*	0.30^⋀
			^∗𝑃=.0003	^⋀𝑃=.01
AC precancer	4 (7.5)	38.5	0.46	0.41
SSCC					0	—	—	—
Total women in study
Pathology	Total case patients.	Age	Brn-3a mRNA	HPV E6 mRNA
	No (%)	Mean	Mean	Mean
Cervicitis	32 + 32 (47.1)	38.3	0.20^∗a	0.17^⋀
SCC precancer	32 + 17 (36)	39.8	0.52*	0.42^⋀
			^∗𝑃=.000052	^⋀𝑃=.00046
AC precancer	17 + 4 (15.4)	41.1	0.46^a	0.42^b
			^a𝑃=.000026	^b𝑃=.0001
SSCC	2 + 0 (1.5)	35	<0.1^†	<0.1^†
			^†0< negligible < 0.1	^†0< negligible < 0.1